横浜市立大学大学院 医学研究科 幹細胞免疫制御内科学血液・リウマチ・感染症内科

MENU

業績

2023年

血液グループ

原著論文: 症例報告を含む

  1. Akahoshi Y, Nakasone H, Takenaka K, Yamasaki S, Nakamura M, Doki N, Tanaka M, Ozawa Y, Uchida N, Ara T, Nakamae H, Ota S, Onizuka M, Yano S, Tanaka J, Fukuda T, Kanda Y, Atsuta Y, Kako S, Yanada M, Arai Y. CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia. Blood Adv, 7(12):2699-2708, 2023.
  2. Akahoshi Y, Tada Y, Sakaida E, Kusuda M, Doki N, Uchida N, Fukuda T, Tanaka M, Sawa M, Katayama Y, Matsuoka KI, Ozawa Y, Onizuka M, Kanda J, Kanda Y, Atsuta Y, Nakasone H. Novel risk assessment for the intensity of conditioning regimen in older patients. Blood Adv, 7(17):4738-4747, 2023.
  3. Aomori M, Matsumoto C, Takebayashi S, Matsuyama N, Uto Y, Tanaka M, Samukawa S, Kato H, Nakajima H, Maeda H: Effects of a smartphone app-based diet and physical activity program for men living with HIV who have dyslipidemia: A pilot randomized controlled trial. Jpn J Nurs Sci, 20(3):e12535, 2023. doi: 10.1111/jjns.12535. Epub 2023 Apr 15. PMID: 37060244.
  4. Araie H, Arai Y, Kida M, Aoki J, Uchida N, Doki N, Fukuda T, Tanaka M, Ozawa Y, Sawa M, Katayama Y, Matsuo Y, Onizuka M, Kanda Y, Kawakita T, Kanda J, Atsuta Y, Yanada M; Adult Acute Myeloid Leukemia Working Group of the Japanese Societyfor Transplantation and Cellular Therapy. Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy. Ann Hematol, 102(10):2879-2893, 2023.
  5. Bramer LM, Hontz RD, Eisfeld AJ, Sims AC, Kim YM, Stratton KG, Nicora CD, Gritsenko MA, Schepmoes AA, Akasaka O, Koga M, Tsutsumi T, Nakamura M, Nakachi I, Baba R, Tateno H, Suzuki S, Nakajima H, Kato H, Ishida K, Ishii M, Uwamino Y, Mitamura K, Paurus VL, Nakayasu ES, Attah IK, Letizia AG, Waters KM, Metz TO, Corson K, Kawaoka Y, Gerbasi VR, Yotsuyanagi H, Iwatsuki-Horimoto K: Multi-omics of NET formation and correlations with CNDP1, PSPB, and L-cystine levels in severe and mild COVID-19 infections. Heliyon, 9(3):e13795, 2023. doi: 10.1016/j.heliyon.2023.e13795. Epub 2023 Mar 7. PMID: 36915486; PMCID: PMC9988701. 
  6. Fuji S, Hakoda A, Kanda J, Fukuda T, Doki N, Katayama Y, Uchida N, Ozawa Y, Kanda Y, Tanaka M, Kataoka K, Ara T, Sawa M, Onizuka M, Onishi Y, Kimura T, Ichinohe T, Atsuta Y, Shintani A, Morishima S. Impact of HLA disparity on overall mortality risk in patients with extensive chronic GVHD: The HLA Working Group of Japanese Society for Transplantation and Cellular Therapy. Bone Marrow Transplant, 58(11):1257-1259, 2023.
  7. Fujii N, Onizuka M, Fukuda T, Ikegame K, Kawakita T, Nakamae H, Kobayashi T, Kataoka K, Tanaka M, Kondo T, Kato K, Sato A, Ichinohe T, Atsuta Y, Ogata M, Suzuki R, Nakasone H; JSTCT Transplant Complications Working Group. Clinical characteristics of late-onset interstitial pneumonia after allogeneic hematopoietic stem cell transplantation. Int J Hematol, 118(2):242-251, 2023.
  8. Hiratsuka T, Ito S, Sakai R, Yokose T, Endo T, Daigo Y, Miyagi Y, Tsuruyama T: Proteome analysis of CD5-positive diffuse large B cell lymphoma FFPE tissue reveals downregulation of DDX3X, DNAJB1, and B cell receptor signaling pathway proteins including BTK and Immunoglobulins. Clin Proteomics,20(1):36, 2023.
  9. Hirose N, Tachibana T, Izumi A, Sato S, Tadera N, Tamai Y, Kanamori H, Tanaka M, Nakajima H. Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia. Hematology, 28(1):2220518 2023.
  10. Ishida H, Shimada H, Tanizawa A, Shimazu Y, Tachibana T, Doki N, Ara T, Matsuo Y, Nara M, Toubai T, Ino K, Nakamae H, Kato K, Kato K, Sato A, Hino M, Matsumoto K, Atsuta Y, Yasui M, Nagamura-Inoue T. Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era. Am J Hematol, 98(8):E200-E203, 2023.
  11. Itonaga H, Miyazaki Y, Aoki K, Shingai N, Ozawa Y, Fukuda T, Kataoka K, Kawakita T, Ueda Y, Ara T, Tanaka M, Katayama Y, Sawa M, Eto T, Kanda J, Atsuta Y, Ishiyama K. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database. Ann Hematol, 102(5):1215-1227, 2023.
  12. Jo T, Arai Y, Oshima S, Kondo T, Harada K, Uchida N, Doki N, Fukuda T, Tanaka M, Ozawa Y, Kuriyama T, Ikegame K, Katayama Y, Ota S, Ara T, Kawakita T, Onizuka M, Ichinohe T, Atsuta Y, Yanada M; Japanese Society for Transplantation and Cellular Therapy (JSTCT). Prognostic impact of complex and/or monosomal karyotypes in post-transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach. Br J Haematol, 202(2):356-368, 2023.
  13. Jo T, Arai Y, Kanda J, Kondo T, Ikegame K, Uchida N, Doki N, Fukuda T, Ozawa Y, Tanaka M, Ara T, Kuriyama T, Katayama Y, Kawakita T, Kanda Y, Onizuka M, Ichinohe T, Atsuta Y, Terakura S. A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Commun Med (Lond), 3(1):67, 2023.
  14. Kako S, Kimura SI, Wada H, Komiya Y, Nakasone H, Sakurai M, Kato J, Tanaka M, Fujii E, Tachibana T, Yamamoto W, Hagihara M, Watanabe R, Yokota A, Nakano H, Mori T, Nakaseko C, Kanamori H, Okamoto S, Kanda Y. Treatment strategy at the decision for allogeneic transplantation in patients with myelodysplastic syndrome in the era of azacitidine: A KSGCT prospective study. Leuk Res, 133:107371, 2023.
  15. Kimura SI, Shimizu H, Miyazaki T, Sakurai M, Tanoue S, Kayamori K, Ohwada C, Yoshimura K, Nakasone H, Ohashi T, Shono K, Tachibana T, Hatano K, Okada K, Kimura Y, Seo S, Doki N, Tanaka M, Hatta Y, Takahashi S, Kanda Y; Kanto Study Group for Cell Therapy: Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, 58(4):452-455, 2023.
  16. Kimura SI, Akahoshi Y, Shiratori S, Okinaka K, Harada K, Uchida N, Doki N, Ikegame K, Nakamae H, Tanaka M, Takada S, Kawakita T, Matsuoka KI, Ara T, Ota S, Sawa M, Onizuka M, Fukuda T, Atsuta Y, Kanda Y, Nakasone H. Association Between Candidemia and Noninfectious Interstitial Pneumonia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. Open Forum Infect Dis, 10(4):ofad163, 2023.
  17. Kim WS, Fukuhara N, Yoon DH, Yamamoto K, Uchida T, Negoro E, Izutsu K, Terui Y, Nakajima H, Ando K, Suehiro Y, Kang HJ, Ko PS, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Tobinai K: Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of an Asian Phase 2 Study. Blood Adv, 7(17):4903-4912, 2023. doi: 10.1182/bloodadvances.2022008615. PMID: 36661315; PMCID: PMC10463191.
  18. Knorr K, Rahman J, Erickson C, Wang E, Monetti M, Li Z, Ortiz-Pacheco J, Jones A, Lu SX, Stanley RF, Baez M, Fox N, Castro C, Marino AE, Jiang C, Penson A, Hogg SJ, Mi X, Nakajima H, Kunimoto H, Nishimura K, Inoue D, Greenbaum B, Knorr D, Ravetch J, Abdel-Wahab O: Systematic evaluation of AML-associated antigens identifies novel anti-U5 SNRNP200 therapeutic antibodies for the treatment of AML. Nat Cancer. 4(12):1675-1692, 2023.
  19. Konuma T, Itonaga H, Ishiyama K, Doki N, Uchida N, Sawa M, Katayama Y, Tanaka M, Ueda Y, Onizuka M, Miyakoshi S, Ozawa Y, Fukuda T, Matsuoka KI, Tanaka J, Kimura T, Ichinohe T, Atsuta Y. Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome? Bone Marrow Transplant, 58(8):893-906, 2023.
  20. Konuma T, Matsuda K, Shimomura Y, Tanoue S, Sugita J, Inamoto Y, Hirayama M, Ara T, Nakamae H, Ota S, Maruyama Y, Eto T, Uchida N, Tanaka M, Ishiwata K, Koi S, Takahashi S, Ozawa Y, Onizuka M, Kanda Y, Kimura T, Ichinohe T, Atsuta Y, Kanda J, Yanada M. Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia. Transplant Cell Ther, 29(6):365.e1-365.e11, 2023.
  21. Konuma T, Kanda J, Uchida N, Nishijima A, Tanaka M, Ozawa Y, Sawa M, Onizuka M, Ota S, Maruyama Y, Kanda Y, Kawakita T, Ara T, Eto T, Nakamae H, Kimura T, Fukuda T, Atsuta Y; Donor/Source Working Group of theJapanese Society for Transplantation and Cellular Therapy. Intensified conditioning regimens improved disease-free survival and engraftment after unrelated single-unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation. Hematol Oncol, 41(1):147-158, 2023.
  22. Kunimoto H, Miura A, Maeda A, Tsuchida N, Uchiyama Y, Kunishita Y, Nakajima Y, Takase-Minegishi K, Yoshimi R, Miyazaki T, Hagihara M, Yamazaki E, Kirino Y, Matsumoto N, Nakajima H: Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome. Int J Hematol, 118(4):494-502, 2023.
  23. Kurosawa S, Yamaguchi T, Mori A, Matsuura T, Masuko M, Murata M,Tashiro H, Kako S, Satake A, Hagihara M, Ota S, Saito T, Kagawa K, Matsuo Y, Itonaga H, Uoshima N, Yamaguchi H, Naito K, Takahashi M, Fukuda T: Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation. J Cancer Surviv, 17(3):781-794, 2023.
  24. Matsuda K, Konuma T, Fuse K, Masuko M, Kawamura K, Hirayama M, Uchida N, Ikegame K, Wake A, Eto T, Doki N, Miyakoshi S, Tanaka M, Takahashi S, Onizuka M, Kato K, Kimura T, Ichinohe T, Takayama N, Kobayashi H, Nakamae H, Atsuta Y, Kanda J, Yanada M. Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study. Br J Haematol, 201(1):106-113, 2023.
  25. Miyazaki K, Sakai R, Iwaki N, Yamamoto G, Murayama K, Nishikori M, Sunami K, Yoshida I, Yano H, Takahashi N, Okamoto A, Munemoto S, Sawazaki A, Suehiro Y, Fukuhara N, Wake A, Arai A, Masaki Y, Toyama K, Yokoyama A, Tsunemine H, Hasegawa Y, Matsumoto K, Yamada T, Nishimura Y, Tamaru S, Asano N, Miyawaki K, Izutsu K, Kinoshita T, Suzuki R, Ohshima K, Kato K, Katayama N, Yamaguchi M: Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL. Cancer Sci,114(6):2689-2691, 2023.
  26. Morishima Y, Watanabe-Okochi N, Kai S, Azuma F, Kimura T, Matsumoto K, Hatasa S, Araki N, Miyamoto A, Sekimoto T, Minemoto M, Ishii H, Uchida N, Takahashi S, Tanaka M, Shingai N, Miyakoshi S, Kozai Y, Onizuka M, Eto T, Ishimaru F, Kanda J, Ichinohe T, Atsuta Y, Takanashi M, Kato K. Selection of Cord Blood Unit by CD34<sup>+</sup> Cell and GM-CFU Numbers and Allele-Level HLA Matching in Single Cord Blood Transplantation. Transplant Cell Ther, 29(10):622-631, 2023.
  27. Nakajima H: Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes. Rinsho Ketsueki, 64(8):753-763, 2023. doi: 10.11406/rinketsu.64.753. PMID: 37673628.
  28. Nakamura Y, Mori T, Kako S, Yamazaki H, Kanda Y, Uchida N, Tanaka M, Nawa Y, Fukuda T, Ichinohe T, Atsuta Y, Onishi Y. Outcome of peripheral blood stem cell transplantation from HLA-identical sibling donors for adult patients with aplastic anemia. Int J Hematol, 117(3):356-365, 2023.
  29. Naoe T, Saito A, Hosono N, Kasahara S, Muto H, Hatano K, Ogura M, Masunari T, Tanaka M, Usuki K, Ishikawa Y, Ando K, Kondo Y, Takagi Y, Takada S, Ishikawa M, Choi I, Sano A, Nagai H. Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide. Cancer Immunol Immunother, 72(8):2865-2871, 2023.
  30. Negoro E, Yamauchi T, Fukuhara N, Yamamoto K, Uchida T, Izutsu K, Maruyama D, Terui Y, Nakajima H, Ando K, Suehiro Y, Choi I, Kanemura N, Nakamura N, Yamamoto G, Maeda Y, Shibayama H, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Kim WS, Tobinai K: Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Exp Hematop, 63(2):108-120, 2023. doi: 10.3960/jslrt.23005. PMID: 37380467; PMCID: PMC10410617.
  31. Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Taniguchi Y, Tanaka M, Kako S, Ichinohe Y, Fukuda T, Ohtake S, Ishikawa Y, Kiyoi H, Matsumura I, Miyazaki Y on behalf of Japan Adult Leukemia Study Group: High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT study. HemaSphere, 7(6):e899, 2023.
  32. Ohashi T, Takase-Minegishi K, Maeda A, Hamada N, Yoshimi R, Kirino Y, Teranaka H, Kunimoto H, Hagihara M, Matsumoto K, Namkoong H, Horita N, Nakajima H: Incidence and risk of hematological adverse events associated with immune checkpoint inhibitors: A systematic literature review and meta-analysis. J Hematol. 12(2):66-74, 2023.
  33. Ohbiki M, Ito Y, Inamoto Y, Miyamura K, Uchida N, Fukuda T, Fujiwara H, Nishida T, Hayashi M, Tanaka M, Kawakita T, Ikegame K, Katayama Y, Ara T, Ichinohe T, Kiyoi H, Matsuo K, Atsuta Y. Improved Long-Term Net Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies over Two Decades. Transplant Cell Ther, 29(12):768.e1-768.e10, 2023.
  34. Okada Y, Kimura F, Kurita N, Takahashi H, Shimazu Y, Mizuno S, Uchida N, Kataoka K, Hiramoto N, Ota S, Kako S, Tsukada N, Kanda Y, Kurahashi S, Doki N, Nishikawa A, Sung-WonKim, Hangaishi A, Kanda J, Fukuda T, Atsuta Y, Kondo E, Kawamura K, Nakasone H: Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma. Cytotherapy, 25(11):1212-1219, 2023.
  35. Otani M, Shiino T, Hachiya A, Gatanaga H, Watanabe D, Minami R, Nishizawa M, Teshima T, Yoshida S, Ito T, Hayashida T, Koga M, Nagashima M, Sadamasu K, Kondo M, Kato S, Uno S, Taniguchi T, Igari H, Samukawa S, Nakajima H, Yoshino Y, Horiba M, Moro H, Watanabe T, Imahashi M, Yokomaku Y, Mori H, Fujii T, Takada K, Nakamura A, Nakamura H, Tateyama M, Matsushita S, Yoshimura K, Sugiura W, Matano T, Kikuchi T: Japanese Drug Resistance HIV-1 Surveillance Network. Association of demographics, HCV co-infection, HIV-1 subtypes and genetic clustering with late HIV diagnosis: a retrospective analysis from the Japanese Drug Resistance HIV-1 Surveillance Network. J Int AIDS Soc, 26(5):e26086, 2023. doi: 10.1002/jia2.26086. PMID: 37221951; PMCID: PMC10206413.
  36. Shimizu H, Najima Y, Kako S, Tanaka M, Fujiwara SI, Mori T, Usuki K, Gotoh M, Hagihara M, Tsukada N, Oniduka M, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Yano S, Ohashi K, Takahashi S, Okamoto S, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT): Clinical significance of late CMV disease in adult patients who underwent allogeneic stem cell transplant. J Infect Chemother, 29(12):1103-1108, 2023.
  37. Shimomura Y, Kitamura T, Nishikubo M, Sobue T, Uchida N, Doki N, Tanaka M, Ito A, Ishikawa J, Ara T, Ota S, Onizuka M, Sawa M, Ozawa Y, Maruyama Y, Ikegame K, Kanda Y, Ichinohe T, Fukuda T, Okamoto S, Teshima T, Atsuta Y. Effect of the COVID-19 pandemic on allogeneic stem cell transplantation in Japan. Int J Hematol, 117(4):590-597, 2023.
  38. Soma S, Murakami K, Fukuchi Y, Kunimoto H, Nakajima H: OGT ensures survival of mouse fetal liver hematopoietic progenitors partly by regulating Bcl-xL and oxidative phosphorylation. Stem Cells. 42(1):55-63, 2023.
  39. Tamaki M, Akahoshi Y, Okada Y, Uchida N, Tanaka M, Doki N, Sawa M, Maruyama Y, Ueda Y, Miyakoshi S, Katayama Y, Kawakita T, Kimura T, Onizuka M, Fukuda T, Atsuta Y, Yanagisawa R, Yakushijin K, Kanda J, Nakasone H. Unrelated female-to-male bone marrow transplantation would be preferred over cord blood transplantation in male patients. Cytotherapy, 25(11):1220-1228, 2023.
  40. Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, Iriyama N, Sato E, Nakazato T, Mitsumori T, Ishikawa M, Fujita H, Kizaki M, Ando M, Hatta Y, Iwanaga E, Kawaguchi T. Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects. Int J Hematol, 118(2):210-220, 2023.
  41. Tsuchiya S, Takaku T, Watanabe N, Iriyama N, Kimura Y, Iwanaga E, Sugimoto KJ, Mitsumori T, Ishikawa M, Nakazato T, Fujita H, Sato E, Hatta Y, Asou N, Kizaki M, Tokuhira M, Ando M, Kawaguchi T. Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice. Intern Med, 62(22):3299-3303, 2023.
  42. Uraki R, Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Chiba S, Sakai-Tagawa Y, Imai M, Kashima Y, Koga M, Fuwa N, Okumura N, Hojo M, Iwamoto N, Kato H, Nakajima H, Ohmagari N, Yotsuyanagi H, Suzuki Y, Kawaoka Y: Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep, 42(12):113580, 2023. doi: 10.1016/j.celrep.2023.113580. Epub 2023 Dec 15. PMID: 38103202.
  43. Wakamatsu M, Murata M, Kanda J, Fukushima K, Fukuda T, Najima Y, Katayama Y, Ozawa Y, Tanaka M, Kanda Y, Eto T, Takada S, Kako S, Uchida N, Kawakita T, Yoshiko H, Ichinohe T, Atsuta Y, Terakura S; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation. Int J Hematol, 117(6):889-899, 2023.
  44. Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, Kamimoto S, Ogura T, Hagiwara S, Kato H, Nakajima H, Uwamino Y, Yagi K, Sugaya N, Nagai H, Saito M, Adachi E, Koga M, Tsutsumi T, Duong C, Okuda M, Murakami J, Furusawa Y, Ujie M, Iwatsuki-Horimoto K, Yotsuyanagi H, Kawaoka Y: Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination. iScience, 26(7):107208, 2023. doi: 10.1016/j.isci.2023.107208. PMID: 37448563; PMCID: PMC10290734.
  45. Yamasaki S, Mizuno S, Iwasaki M, Seo S, Uchida N, Shigesaburo M, Nakano N, Ishiwata K, Uehara Y, Eto T, Takase K, Kawakita T, Tanaka M, Sawa M, Katayama Y, Nawa Y, Makoto O, Ichinohe T, Atsuta Y, Kanda J, Yanada M. Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics. Ann Hematol, 102(6):1549-1559, 2023.
  46. Yanada M, Shimomura Y, Mizuno S, Matsuda K, Kondo T, Doki N, Tanaka M, Fukuda T, Ara T, Uchida N, Onizuka M, Sawa M, Ozawa Y, Hiramoto N, Ota S, Kanda J, Kanda Y, Ichinohe T, Okamoto S, Atsuta Y, Konuma T. External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia. Bone Marrow Transplant, 58(10):1096-1103, 2023.
  47. Yanada M, Yamasaki S, Konuma T, Mizuno S, Uchida N, Onai D, Fukuda T, Tanaka M, Ozawa Y, Eto T, Ikegame K, Sawa M, Katayama Y, Kawakita T, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Yano S. Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. Int J Hematol, 117(3):398-408, 2023.
  48. Yanagisawa R, Hirakawa T, Doki N, Ikegame K, Matsuoka KI, Fukuda T, Nakamae H, Ota S, Hiramoto N, Ishikawa J, Ara T, Tanaka M, Koga Y, Kawakita T, Maruyama Y, Kanda Y, Hino M, Atsuta Y, Yabe H, Tsukada N. Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors. Int J Hematol. 2023 Mar;117(3):421-427.
  49. Yanagisawa R, Tamaki M, Tanoshima R, Misaki Y, Uchida N, Koi S, Tanaka T, Ozawa Y, Matsuo Y, Tanaka M, Ikegame K, Katayama Y, Matsuoka KI, Ara T, Kanda Y, Matsumoto K, Fukuda T, Atsuta Y, Kato M, Nakasone H. Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group. Hematol Oncol, 41(3):535-545, 2023.
  50. Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, Onizuka M, Yokose N, Fujimaki K, Hagihara M, Oshikawa G, Murayama K, Kumagai T, Kimura S, Najima Y, Iriyama N, Tsutsumi I, Oba K, Kojima H, Sakamaki H, Inokuchi K; Kanto CML Study Group. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study. Int J Hematol, 117:694-705, 2023.
  51. 香月健吾, 中嶋ゆき, 穐本昌寛, 佐久間敬之, 松村彩子, 宮崎拓也, 前田晃樹, 澤住知枝, 藤澤 信, 中島秀明: 初回化学療法後に膵液瘻と腹膜炎を発症したびまん性大細胞型B細胞リンパ腫. 臨床血液, 64(2):125-129, 2023.
  52. 長谷川広大, 松村彩子, 香月健吾, 穐本昌寛, 佐久間敬之, 中嶋ゆき, 宮崎拓也, 藤澤 信, 中島秀明:筋強直性ジストロフィーに合併した縦隔原発大細胞型B細胞性リンパ腫.臨床血液, 64(10):1286-1288, 2023.
  53. 宮下愛, 黒沢貴之, 矢島智志, 山﨑悦子:SARS-CoV-2 RNA測定装置GenPadの性能評価. 日本臨床検査医学会誌, 71(10):684-687, 2023.

総説

  1. 藤田浩之: 発熱性好中球減少症. 血液内科, 87(6): 599-605, 2023. 科学評論社.
  2. 山﨑悦子:「血液専門医」と「臨床検査専門医」:二足の草鞋をはいて. 臨床血液, 64(8): 799-802, 2023.
  3. 山﨑悦子: ALLにおける測定可能残存病変の意義と活用法. 特集 急性リンパ芽球性白血病(ALL) 月刊「血液内科」, 87(1), 2023. 科学評論社.

著書

  1. 高橋寛行: 造血器腫瘍診療ガイドライン2023年版,一部執筆,.金原出版株式会社, 2023.
  2. 橋寛行: がん化学療法の薬―抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬―はや調べノート2023・2024年版一部執筆. メディカ出版, 2023.
  3. 高橋寛行: 日本臨床増刊号-新リンパ腫学 基礎・臨床の最新動向, 乳腺リンパ腫. 417-422,2023.
  4. 立花崇孝: 【これだけは押さえておきたい がん化学療法の薬 抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬 はや調べノート】分子標的薬 BTK阻害薬 アカラブルチニブ(解説) YORi-SOUがんナーシング(2433-7390)別冊がん化学療法の薬-抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬-はや調べノート2023・2024年版. メディカ出版, 146-147, 2023.
  5. 立花崇孝: 【これだけは押さえておきたい がん化学療法の薬 抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬 はや調べノート】分子標的薬 STAMP阻害薬 アシミニブ塩酸塩.YORi-SOUがんナーシング(2433-7390)別冊がん化学療法の薬-抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬-はや調べノート2023・2024年版. メディカ出版, 172-173, 2023.
  6. 藤田浩之: 急性前骨髄球性白血病(執筆責任者)造血器腫瘍診療ガイドライン2023年版. 金原出版, 47-66, 2023.
  7. 山﨑悦子: 急性リンパ芽球性白血病/リンパ芽球性リンパ腫(ALL/LBL). 日本血液学会編 造血器腫瘍診療ガイドライン 2023年版. 金原出版, 67-95, 2023.
  8. 山﨑悦子: 血液専門医試験過去問-解答・解説. 宮﨑泰司、張替秀郎編集血液専門医テキスト(改定第4版). 南江堂, 579-615, 2023.

検索 ページトップへ